Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Net Income (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Net Income data on record, last reported at -$6.2 million in Q4 2025.

  • For Q4 2025, Net Income rose 72.97% year-over-year to -$6.2 million; the TTM value through Dec 2025 reached -$64.2 million, up 43.43%, while the annual FY2025 figure was -$66.4 million, 42.52% up from the prior year.
  • Net Income reached -$6.2 million in Q4 2025 per TARS's latest filing, up from -$12.7 million in the prior quarter.
  • Across five years, Net Income topped out at $10.4 million in Q1 2021 and bottomed at -$42.5 million in Q4 2023.
  • Average Net Income over 5 years is -$19.4 million, with a median of -$21.3 million recorded in 2022.
  • Peak YoY movement for Net Income: soared 631.94% in 2021, then crashed 420.98% in 2023.
  • A 5-year view of Net Income shows it stood at -$14.5 million in 2021, then rose by 5.96% to -$13.6 million in 2022, then tumbled by 211.62% to -$42.5 million in 2023, then surged by 45.63% to -$23.1 million in 2024, then surged by 72.97% to -$6.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$6.2 million in Q4 2025, -$12.7 million in Q3 2025, and -$20.2 million in Q2 2025.